Abstract
A series of pyrazolo[4,3-d]pyrimidine sulfonamides and pyrazolo[3,4-d]pyrimidine sulfonamides have been synthesized. These compounds increase transcription of a calcitonin-luciferase promoter and production of cellular calcitonin in a calcitonin-secretion/RIA assay with minimized phosphodiesterase type 4 inhibitory activity at 30 microM as compared to structurally related xanthine methylene ketones such as denbufyllene. These two series are notable examples of small molecules that act as CT-inducers, a method to potentially treat bone loss diseases.
MeSH terms
-
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors
-
Calcitonin / biosynthesis*
-
Calcitonin / genetics
-
Cell Line
-
Cyclic Nucleotide Phosphodiesterases, Type 4
-
Genes, Reporter
-
Humans
-
Luciferases / genetics
-
Luciferases / metabolism
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / chemistry
-
Phosphodiesterase Inhibitors / pharmacology
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology
-
Radioimmunoassay
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis*
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology
-
Transcriptional Activation
-
Xanthines / chemistry
-
Xanthines / pharmacology
Substances
-
Phosphodiesterase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Xanthines
-
denbufylline
-
Calcitonin
-
Luciferases
-
3',5'-Cyclic-AMP Phosphodiesterases
-
Cyclic Nucleotide Phosphodiesterases, Type 4